hould there be a doorstop in the revolving door between drug makers and regulatory agencies?

Several U.S. senators believe so, and on Thursday they introduced legislation  that would take two steps to slow the pace at which individuals move between the pharmaceutical industry and both the Food and Drug Administration and the Drug Enforcement Administration.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.